img

Global Refractory Multiple Myeloma Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Refractory Multiple Myeloma Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Refractory Multiple Myeloma Market
Global Refractory Multiple Myeloma market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Refractory Multiple Myeloma industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Globally, Refractory Multiple Myeloma key companies include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG and Takeda Pharmaceutical Company Limited, etc. Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc. are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Refractory Multiple Myeloma were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Refractory Multiple Myeloma market and estimated to attract more attentions from industry insiders and investors.
Refractory Multiple Myeloma can be divided into Proteosome Inhibitor, Immunomodulators, Anti-CD38 Monoclonal Antibody and Others, etc. Proteosome Inhibitor is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Refractory Multiple Myeloma is widely used in various fields, such as Hospital, Specialty Clinic and Others,, etc. Hospital provides greatest supports to the Refractory Multiple Myeloma industry development. In 2022, global % revenue of Refractory Multiple Myeloma went into Hospital filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Refractory Multiple Myeloma market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Refractory Multiple Myeloma market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Segment by Type
Proteosome Inhibitor
Immunomodulators
Anti-CD38 Monoclonal Antibody
Others

Segment by Application


Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Refractory Multiple Myeloma introduction, etc. Refractory Multiple Myeloma Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Refractory Multiple Myeloma
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Refractory Multiple Myeloma Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Proteosome Inhibitor
1.2.3 Immunomodulators
1.2.4 Anti-CD38 Monoclonal Antibody
1.2.5 Others
1.3 Market by Application
1.3.1 Global Refractory Multiple Myeloma Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Refractory Multiple Myeloma Market Perspective (2018-2033)
2.2 Global Refractory Multiple Myeloma Growth Trends by Region
2.2.1 Refractory Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Refractory Multiple Myeloma Historic Market Size by Region (2018-2023)
2.2.3 Refractory Multiple Myeloma Forecasted Market Size by Region (2024-2033)
2.3 Refractory Multiple Myeloma Market Dynamics
2.3.1 Refractory Multiple Myeloma Industry Trends
2.3.2 Refractory Multiple Myeloma Market Drivers
2.3.3 Refractory Multiple Myeloma Market Challenges
2.3.4 Refractory Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Refractory Multiple Myeloma by Players
3.1.1 Global Refractory Multiple Myeloma Revenue by Players (2018-2023)
3.1.2 Global Refractory Multiple Myeloma Revenue Market Share by Players (2018-2023)
3.2 Global Refractory Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Refractory Multiple Myeloma, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Refractory Multiple Myeloma Market Concentration Ratio
3.4.1 Global Refractory Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Refractory Multiple Myeloma Revenue in 2022
3.5 Global Key Players of Refractory Multiple Myeloma Head office and Area Served
3.6 Global Key Players of Refractory Multiple Myeloma, Product and Application
3.7 Global Key Players of Refractory Multiple Myeloma, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Refractory Multiple Myeloma Breakdown Data by Type
4.1 Global Refractory Multiple Myeloma Historic Market Size by Type (2018-2023)
4.2 Global Refractory Multiple Myeloma Forecasted Market Size by Type (2024-2033)
5 Refractory Multiple Myeloma Breakdown Data by Application
5.1 Global Refractory Multiple Myeloma Historic Market Size by Application (2018-2023)
5.2 Global Refractory Multiple Myeloma Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Refractory Multiple Myeloma Market Size (2018-2033)
6.2 North America Refractory Multiple Myeloma Market Size by Type
6.2.1 North America Refractory Multiple Myeloma Market Size by Type (2018-2023)
6.2.2 North America Refractory Multiple Myeloma Market Size by Type (2024-2033)
6.2.3 North America Refractory Multiple Myeloma Market Share by Type (2018-2033)
6.3 North America Refractory Multiple Myeloma Market Size by Application
6.3.1 North America Refractory Multiple Myeloma Market Size by Application (2018-2023)
6.3.2 North America Refractory Multiple Myeloma Market Size by Application (2024-2033)
6.3.3 North America Refractory Multiple Myeloma Market Share by Application (2018-2033)
6.4 North America Refractory Multiple Myeloma Market Size by Country
6.4.1 North America Refractory Multiple Myeloma Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Refractory Multiple Myeloma Market Size by Country (2018-2023)
6.4.3 North America Refractory Multiple Myeloma Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Refractory Multiple Myeloma Market Size (2018-2033)
7.2 Europe Refractory Multiple Myeloma Market Size by Type
7.2.1 Europe Refractory Multiple Myeloma Market Size by Type (2018-2023)
7.2.2 Europe Refractory Multiple Myeloma Market Size by Type (2024-2033)
7.2.3 Europe Refractory Multiple Myeloma Market Share by Type (2018-2033)
7.3 Europe Refractory Multiple Myeloma Market Size by Application
7.3.1 Europe Refractory Multiple Myeloma Market Size by Application (2018-2023)
7.3.2 Europe Refractory Multiple Myeloma Market Size by Application (2024-2033)
7.3.3 Europe Refractory Multiple Myeloma Market Share by Application (2018-2033)
7.4 Europe Refractory Multiple Myeloma Market Size by Country
7.4.1 Europe Refractory Multiple Myeloma Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Refractory Multiple Myeloma Market Size by Country (2018-2023)
7.4.3 Europe Refractory Multiple Myeloma Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Refractory Multiple Myeloma Market Size (2018-2033)
8.2 China Refractory Multiple Myeloma Market Size by Type
8.2.1 China Refractory Multiple Myeloma Market Size by Type (2018-2023)
8.2.2 China Refractory Multiple Myeloma Market Size by Type (2024-2033)
8.2.3 China Refractory Multiple Myeloma Market Share by Type (2018-2033)
8.3 China Refractory Multiple Myeloma Market Size by Application
8.3.1 China Refractory Multiple Myeloma Market Size by Application (2018-2023)
8.3.2 China Refractory Multiple Myeloma Market Size by Application (2024-2033)
8.3.3 China Refractory Multiple Myeloma Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Refractory Multiple Myeloma Market Size (2018-2033)
9.2 Asia Refractory Multiple Myeloma Market Size by Type
9.2.1 Asia Refractory Multiple Myeloma Market Size by Type (2018-2023)
9.2.2 Asia Refractory Multiple Myeloma Market Size by Type (2024-2033)
9.2.3 Asia Refractory Multiple Myeloma Market Share by Type (2018-2033)
9.3 Asia Refractory Multiple Myeloma Market Size by Application
9.3.1 Asia Refractory Multiple Myeloma Market Size by Application (2018-2023)
9.3.2 Asia Refractory Multiple Myeloma Market Size by Application (2024-2033)
9.3.3 Asia Refractory Multiple Myeloma Market Share by Application (2018-2033)
9.4 Asia Refractory Multiple Myeloma Market Size by Region
9.4.1 Asia Refractory Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Refractory Multiple Myeloma Market Size by Region (2018-2023)
9.4.3 Asia Refractory Multiple Myeloma Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Type
10.2.1 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Application
10.3.1 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country
10.4.1 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Details
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Introduction
11.1.4 Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.1.5 Bristol Myers Squibb Recent Developments
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Teva Pharmaceutical Industries Ltd. Company Details
11.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Introduction
11.2.4 Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Details
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Refractory Multiple Myeloma Introduction
11.3.4 Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.3.5 Pfizer Inc. Recent Developments
11.4 Janssen Global Services, LLC
11.4.1 Janssen Global Services, LLC Company Details
11.4.2 Janssen Global Services, LLC Business Overview
11.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Introduction
11.4.4 Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.4.5 Janssen Global Services, LLC Recent Developments
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Details
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Introduction
11.5.4 Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.5.5 Gilead Sciences, Inc. Recent Developments
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Company Details
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Refractory Multiple Myeloma Introduction
11.6.4 Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.6.5 Fresenius Kabi Recent Developments
11.7 GSK plc.
11.7.1 GSK plc. Company Details
11.7.2 GSK plc. Business Overview
11.7.3 GSK plc. Refractory Multiple Myeloma Introduction
11.7.4 GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.7.5 GSK plc. Recent Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Refractory Multiple Myeloma Introduction
11.8.4 Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.8.5 Novartis AG Recent Developments
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Details
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.9.5 Takeda Pharmaceutical Company Limited Recent Developments
11.10 Genentech, Inc.
11.10.1 Genentech, Inc. Company Details
11.10.2 Genentech, Inc. Business Overview
11.10.3 Genentech, Inc. Refractory Multiple Myeloma Introduction
11.10.4 Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.10.5 Genentech, Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Refractory Multiple Myeloma Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Proteosome Inhibitor
Table 3. Key Players of Immunomodulators
Table 4. Key Players of Anti-CD38 Monoclonal Antibody
Table 5. Key Players of Others
Table 6. Global Refractory Multiple Myeloma Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 7. Global Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Refractory Multiple Myeloma Market Share by Region (2018-2023)
Table 10. Global Refractory Multiple Myeloma Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Refractory Multiple Myeloma Market Share by Region (2024-2033)
Table 12. Refractory Multiple Myeloma Market Trends
Table 13. Refractory Multiple Myeloma Market Drivers
Table 14. Refractory Multiple Myeloma Market Challenges
Table 15. Refractory Multiple Myeloma Market Restraints
Table 16. Global Refractory Multiple Myeloma Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Refractory Multiple Myeloma Revenue Share by Players (2018-2023)
Table 18. Global Top Refractory Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2022)
Table 19. Global Refractory Multiple Myeloma Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Refractory Multiple Myeloma Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Refractory Multiple Myeloma, Headquarters and Area Served
Table 22. Global Key Players of Refractory Multiple Myeloma, Product and Application
Table 23. Global Key Players of Refractory Multiple Myeloma, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Refractory Multiple Myeloma Revenue Market Share by Type (2018-2023)
Table 27. Global Refractory Multiple Myeloma Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Refractory Multiple Myeloma Revenue Market Share by Type (2024-2033)
Table 29. Global Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Refractory Multiple Myeloma Revenue Share by Application (2018-2023)
Table 31. Global Refractory Multiple Myeloma Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Refractory Multiple Myeloma Revenue Share by Application (2024-2033)
Table 33. North America Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 35. North America Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 37. North America Refractory Multiple Myeloma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. North America Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 40. Europe Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 42. Europe Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 44. Europe Refractory Multiple Myeloma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Europe Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 47. China Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 49. China Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 51. Asia Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 53. Asia Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 55. Asia Refractory Multiple Myeloma Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 56. Asia Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Refractory Multiple Myeloma Market Size by Region (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Refractory Multiple Myeloma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 63. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 65. Bristol Myers Squibb Company Details
Table 66. Bristol Myers Squibb Business Overview
Table 67. Bristol Myers Squibb Refractory Multiple Myeloma Product
Table 68. Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 69. Bristol Myers Squibb Recent Developments
Table 70. Teva Pharmaceutical Industries Ltd. Company Details
Table 71. Teva Pharmaceutical Industries Ltd. Business Overview
Table 72. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product
Table 73. Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 74. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 75. Pfizer Inc. Company Details
Table 76. Pfizer Inc. Business Overview
Table 77. Pfizer Inc. Refractory Multiple Myeloma Product
Table 78. Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 79. Pfizer Inc. Recent Developments
Table 80. Janssen Global Services, LLC Company Details
Table 81. Janssen Global Services, LLC Business Overview
Table 82. Janssen Global Services, LLC Refractory Multiple Myeloma Product
Table 83. Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 84. Janssen Global Services, LLC Recent Developments
Table 85. Gilead Sciences, Inc. Company Details
Table 86. Gilead Sciences, Inc. Business Overview
Table 87. Gilead Sciences, Inc. Refractory Multiple Myeloma Product
Table 88. Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 89. Gilead Sciences, Inc. Recent Developments
Table 90. Fresenius Kabi Company Details
Table 91. Fresenius Kabi Business Overview
Table 92. Fresenius Kabi Refractory Multiple Myeloma Product
Table 93. Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 94. Fresenius Kabi Recent Developments
Table 95. GSK plc. Company Details
Table 96. GSK plc. Business Overview
Table 97. GSK plc. Refractory Multiple Myeloma Product
Table 98. GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 99. GSK plc. Recent Developments
Table 100. Novartis AG Company Details
Table 101. Novartis AG Business Overview
Table 102. Novartis AG Refractory Multiple Myeloma Product
Table 103. Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 104. Novartis AG Recent Developments
Table 105. Takeda Pharmaceutical Company Limited Company Details
Table 106. Takeda Pharmaceutical Company Limited Business Overview
Table 107. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product
Table 108. Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 109. Takeda Pharmaceutical Company Limited Recent Developments
Table 110. Genentech, Inc. Company Details
Table 111. Genentech, Inc. Business Overview
Table 112. Genentech, Inc. Refractory Multiple Myeloma Product
Table 113. Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 114. Genentech, Inc. Recent Developments
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Refractory Multiple Myeloma Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Refractory Multiple Myeloma Market Share by Type: 2022 VS 2033
Figure 3. Proteosome Inhibitor Features
Figure 4. Immunomodulators Features
Figure 5. Anti-CD38 Monoclonal Antibody Features
Figure 6. Others Features
Figure 7. Global Refractory Multiple Myeloma Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 8. Global Refractory Multiple Myeloma Market Share by Application: 2022 VS 2033
Figure 9. Hospital Case Studies
Figure 10. Specialty Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Refractory Multiple Myeloma Report Years Considered
Figure 13. Global Refractory Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Refractory Multiple Myeloma Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Refractory Multiple Myeloma Market Share by Region: 2022 VS 2033
Figure 16. Global Refractory Multiple Myeloma Market Share by Players in 2022
Figure 17. Global Top Refractory Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Refractory Multiple Myeloma Revenue in 2022
Figure 19. North America Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 21. North America Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 22. North America Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 23. United States Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Refractory Multiple Myeloma Market Size YoY (2018-2033) & (US$ Million)
Figure 26. Europe Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 27. Europe Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 28. Europe Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 29. Germany Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. France Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. U.K. Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Italy Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Russia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Nordic Countries Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. China Refractory Multiple Myeloma Market Size YoY (2018-2033) & (US$ Million)
Figure 36. China Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 37. China Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 38. Asia Refractory Multiple Myeloma Market Size YoY (2018-2033) & (US$ Million)
Figure 39. Asia Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 40. Asia Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 41. Asia Refractory Multiple Myeloma Market Share by Region (2018-2033)
Figure 42. Japan Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. South Korea Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. China Taiwan Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Southeast Asia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. India Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Australia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Size YoY (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 50. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 51. Middle East, Africa, and Latin America Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 52. Brazil Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Mexico Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Turkey Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Saudi Arabia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Israel Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. GCC Countries Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. Bristol Myers Squibb Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 59. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 60. Pfizer Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 61. Janssen Global Services, LLC Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 62. Gilead Sciences, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 63. Fresenius Kabi Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 64. GSK plc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 65. Novartis AG Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 66. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 67. Genentech, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries